Repligen Corp
RGEN: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| tZ@ | LOCK|tZ%L | LOCK|XC$#&$&Z |
Repligen Earnings: Excellent Profit Margins, China Recovery Underway
Repligen reported second-quarter year-on-year organic revenue growth of 13% and adjusted EBITDA margin expansion of 3.8 percentage points. Management raised 2026 guidance for organic revenue growth to 10.5%-13.5% from 9.0%-13.0% and adjusted EBITDA margin to 20.6%-21.0% from 20.3%-20.8%.
